ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

SABSW SAB Biotherapeutics Inc

0.0251
0.0001 (0.40%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
SAB Biotherapeutics Inc SABSW NASDAQ Warrant Capital Accionario
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0001 0.40% 0.0251 18:50:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.025 0.025 0.0253 0.0251 0.025
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/5/202416:15EDGAR2Form DEF 14A - Other definitive proxy statements
21/5/202406:30EDGAR2Form 8-K - Current report
20/5/202416:45GLOBESAB Biotherapeutics Announces Q1 2024 Financial Results and..
20/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202406:15GLOBESAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of..
16/4/202406:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202406:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202406:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202406:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/3/202409:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
23/2/202407:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/2/202407:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202406:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
23/1/202416:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
02/1/202415:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
29/11/202306:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
20/11/202306:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
14/11/202306:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202306:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
09/11/202306:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
24/10/202306:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
19/10/202306:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202306:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02/10/202306:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21/8/202307:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/6/202307:30GLOBESAB Biotherapeutics Presents Positive IND-Enabling GLP..

Su Consulta Reciente

Delayed Upgrade Clock